The Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, along with Federation of Indian Chambers of Commerce & Industry (FICCI), is organizing ‘India Pharma & India Medical Device 2018’, with the theme - ‘Affordable and Quality Healthcare’, the 3rd International exhibition and conference on Pharmaceutical & Medical Device sector from 15th-17th February, 2018 in Bengaluru.
[adsense:336x280:8701650588]
The increasing commercial collaboration between U.S. and Indian pharmaceutical companies is indicative of the ways in which U.S. companies are increasing their revenues from India and spreading their development costs. In view of such several development points, Indian pharma body urged U.S. Trade Representative (USTR) to remove India from Priority Watch List.
Directorate General of Health Services (DGHS) Office of Drugs Controller General (India) orders port offices to release all the consignments of imported Insulin formulations including consignments released on letter to avoid shortage of such lifesaving drugs.
There has been a 66% decline in the estimated number of annual new HIV infections in the country from 2000 to 2015, against the global average of 35%.
As per National Health Accounts Estimates for India 2014-15, the total health expenditure per capita is estimated to be Rs. 3826.
Smt. Anupriya Patel, Minister of State for Health and Family Welfare reviewed the activities of National Centre for Disease Control and issued necessary directions for disease surveillance, monitoring of health status, educating the public, providing evidence for public health action and enforcing public health regulations. She also visited the Epidemiology & Disease Control Complex and interacted with India Epidemic Intelligence Service (EIS) officers undergoing two years training at NCDC in collaboration with CDC Atlanta under Global Health Security Agenda (GHSA). During her visit at the Strategic Health Operations Centre (SHOC), the MoS (Health) reviewed the Seasonal Influenza (H1N1) status through video conferencing with the States of Rajasthan, Gujarat and Uttar Pradesh.
It is noticed that that there will be almost no impact on the prices of non-scheduled formulations which account for nearly 80% of the total pharmaceuticals sector, analysed by government.
National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices or retail prices of 65 scheduled formulations under Drugs Prices Control Order, 2013 (DPCO). It includes 63 formulations, 1 scheduled formulation of Schedule-I and 1 scheduled formulations of Schedule-I under para 19 of DPCO.
Maharashtra Registered Pharmacists Association (MRPA)'s demand from health ministry to allow Pharmacist (chemist) to suggest or supply cheaper alternative generic substitute of same ingredients of branded drug molecule proscribed by doctors so that people could have access to drugs at lower prices.
In last month, there was lot of hike about osemertinib is being sold illegally in the Hyderabad by private and government hospitals despite a ban by the Drug Controller General of India (DCGI). But on last Friday, DCGI confirmed that only AstraZeneca Pharma India Limited, Bangalore has given permission for import and marketing of cancer drug.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
